Literature DB >> 7545241

Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.

M D Lairmore1, A M DiGeorge, S F Conrad, A V Trevino, R B Lal, P T Kaumaya.   

Abstract

Conventional strategies of viral peptide immunizations often elicit low-affinity antibody responses and have limited ability to elicit immune responses in outbred animals of diverse major histocompatibility (MHC) haplotypes. This genetically restricted T-cell-stimulatory activity of peptides is a serious obstacle to vaccine design. However, the use of promiscuous T-cell epitopes may circumvent this problem. Promiscuous T-cell epitopes from tetanus toxin (amino acids [aa] 580 to 599) and the measles virus F protein (aa 288 to 302) that bind to several isotypic and allotypic forms of human MHC class II molecules have been identified and have been used in highly immunogenic constructs to overcome haplotype-restricted immune responses. Chimeric and beta-template peptide constructs incorporating known human T-lymphotropic virus type 1 (HTLV-1) B- and T-cell epitopes from the surface envelope protein gp46 (SP2 [aa 86 to 107] and SP4a [aa 190 to 209]) and promiscuous T-cell peptides were synthesized, and their immunogenicities were evaluated in both rabbits and mouse strains of divergent haplotypes (C3H/HeJ [H-2k], C57BL/6 [H-2b], and BALB/c [H-2d]). In addition, peptide preparations were structurally characterized by analytical high-performance liquid chromatography, mass spectrometry, and circular dichroism. In contrast to their linear forms, the chimeric constructs of both the SP2 and SP4a epitopes displayed alpha-helical secondary structures. Immunogenicity of the peptide constructs was evaluated by direct and competitive enzyme-linked immunosorbant assay (ELISA), as well as by radioimmunoprecipitation, syncytium inhibition, and antigen-induced lymphocyte proliferation assays. Immunization with the SP4a peptide without conjugation to a carrier protein produced antibodies specific for SP4a in two mouse strains (C3H/HeJ and C57BL/6). However, BALB/c mice failed to respond to the peptide, indicating that the T-cell epitope of the SP4a sequence is MHC restricted. In contrast, the chimeric constructs MVF-SP2 and SP4a-measles virus F protein were highly immunogenic, producing elevated ELISA titers after only two immunizations. Elicited antibodies recognized native forms of gp46 in ELISAs and radioimmunoprecipitation assays, as well as inhibited HTLV-1-mediated syncytium formation. In addition, chimeric constructs were effective at induction of lymphocyte proliferation to the T-cell epitope, SP4a, in each strain of immunized mice. Our data demonstrate that the antibody response to retroviral peptides is enhanced by promiscuous peptide constructs, in part because of the ability of such constructs to promote appropriate secondary structural forms of viral epitopes. In addition, these constructs promote virus-specific helper T-cell responses, thereby overcoming genetically restricted immune responses to the synthetic peptides.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545241      PMCID: PMC189504     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution.

Authors:  A G Amit; R A Mariuzza; S E Phillips; R J Poljak
Journal:  Science       Date:  1986-08-15       Impact factor: 47.728

Review 2.  Prediction of the secondary structure of proteins from their amino acid sequence.

Authors:  P Y Chou; G D Fasman
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1978

3.  Determination of the helix and beta form of proteins in aqueous solution by circular dichroism.

Authors:  Y H Chen; J T Yang; K H Chau
Journal:  Biochemistry       Date:  1974-07-30       Impact factor: 3.162

4.  Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells.

Authors:  A Sette; S Buus; S Colon; J A Smith; C Miles; H M Grey
Journal:  Nature       Date:  1987 Jul 30-Aug 5       Impact factor: 49.962

5.  Binding of immunogenic peptides to Ia histocompatibility molecules.

Authors:  B P Babbitt; P M Allen; G Matsueda; E Haber; E R Unanue
Journal:  Nature       Date:  1985 Sep 26-Oct 2       Impact factor: 49.962

6.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

7.  Human T-cell leukemia virus type I: induction of syncytia and inhibition by patients' sera.

Authors:  K Nagy; P Clapham; R Cheingsong-Popov; R A Weiss
Journal:  Int J Cancer       Date:  1983-09-15       Impact factor: 7.396

8.  A method for preparing beta-hCG COOH peptide-carrier conjugates of predictable composition.

Authors:  A C Lee; J E Powell; G W Tregear; H D Niall; V C Stevens
Journal:  Mol Immunol       Date:  1980-06       Impact factor: 4.407

9.  Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.

Authors:  Y Tanaka; L Zeng; H Shiraki; H Shida; H Tozawa
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

10.  Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

Authors:  A Gessain; F Barin; J C Vernant; O Gout; L Maurs; A Calender; G de Thé
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

View more
  12 in total

1.  In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.

Authors:  Hiroya Kobayashi; Toshihiro Ngato; Keisuke Sato; Naoko Aoki; Shoji Kimura; Yuetsu Tanaka; Hitoshi Aizawa; Masatoshi Tateno; Esteban Celis
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

2.  Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection.

Authors:  L O Bakaletz; B J Kennedy; L A Novotny; G Duquesne; J Cohen; Y Lobet
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

Review 3.  Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

4.  A P5 peptide that is homologous to peptide 10 of OprF from Pseudomonas aeruginosa enhances clearance of nontypeable Haemophilus influenzae from acutely infected rat lung in the absence of detectable peptide-specific antibody.

Authors:  D C Webb; A W Cripps
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

5.  Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model.

Authors:  Rashade A H Haynes; Evan Ware; Christopher Premanandan; Bevin Zimmerman; Lianbo Yu; Andrew J Phipps; Michael D Lairmore
Journal:  Blood       Date:  2009-11-20       Impact factor: 22.113

6.  Production of tag-free recombinant fusion protein encompassing promiscuous T cell epitope of tetanus toxoid and dog zona pellucida glycoprotein-3 for contraceptive vaccine development.

Authors:  Neha Gupta; Abhinav Shrestha; Amulya Kumar Panda; Satish Kumar Gupta
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

7.  Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides.

Authors:  Inna G Ovsyannikova; Kenneth L Johnson; David C Muddiman; Robert A Vierkant; Gregory A Poland
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.

Authors:  Kevin Chu Foy; Ruthie M Wygle; Megan J Miller; Jay P Overholser; Tanios Bekaii-Saab; Pravin T P Kaumaya
Journal:  J Immunol       Date:  2013-05-22       Impact factor: 5.422

9.  In vitro CD4+ lymphocyte transformation and infection in a rabbit model with a molecular clone of human T-cell lymphotrophic virus type 1.

Authors:  N D Collins; G C Newbound; L Ratner; M D Lairmore
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

Review 10.  Peptide-based synthetic vaccines.

Authors:  Mariusz Skwarczynski; Istvan Toth
Journal:  Chem Sci       Date:  2015-12-17       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.